PMC · DOI:10.1002/jha2.70182·November 20, 2025
Lynozyfic (Linvoseltamab): A First‐in‐Class Off‐the‐Shelf T‐Cell Redirector for Refractory Multiple Myeloma
Raza Ur Rehman
Abstract
Linked entities
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Diseases1
Figures1
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCAR-T cell therapy research · Multiple Myeloma Research and Treatments · vaccines and immunoinformatics approaches